Announcements
- Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation
- Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
- Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
- Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day
- Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates
- Terns Pharmaceuticals Announces Leadership Changes
- Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024
- Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
- Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation
- Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
More ▼
Key statistics
On Tuesday, Terns Pharmaceuticals Inc (430:FRA) closed at 6.20, -21.32% below its 52-week high of 7.88, set on Jul 03, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.10 |
---|---|
High | 6.20 |
Low | 6.05 |
Bid | 6.00 |
Offer | 6.50 |
Previous close | 6.20 |
Average volume | 10.00 |
---|---|
Shares outstanding | 64.68m |
Free float | 63.52m |
P/E (TTM) | -- |
Market cap | 443.04m USD |
EPS (TTM) | -1.26 USD |
Data delayed at least 15 minutes, as of Jul 02 2024 20:55 BST.
More ▼